#ASCO21: Merck keeps chopping away at a path to early cancer patients for Keytruda, this time in kidney
In the forever war between blockbuster checkpoint inhibitors, Merck’s wonder drug Keytruda has taken a clear edge over its nearest rivals in metastatic, unresectable cancer. But on the misty frontier of early-stage therapy — where surgery is still an option and cures a distant possibility — the game is still very much afoot, and Merck continues feverishly building Keytruda’s case.
At a little-more-than-two-year checkup, Merck’s Keytruda cut the risk of cancer relapse or death by 32% compared with placebo in renal cell carcinoma patients with a mid-to-high risk of recurrence after a kidney removal, or after removal of a kidney and metastatic lesions, according to late-breaking data from the Phase III KEYNOTE-564 set to be presented at #ASCO21 this weekend.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.